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Abstract 27 
Molluscum contagiosum virus (MCV) causes persistent, benign skin neoplasm in children and 28 
adults. MCV is refractive to growth in standard tissue culture and there is no relevant animal 29 
model of infection. Here we investigated if another poxvirus (vaccinia virus; VACV) could be 30 
used to examine MCV immunoevasion protein properties in vivo. The MCV MC159L or MC160L 31 
gene, which encode NF-κB antagonists, were inserted into an attenuated VACV lacking an NF-32 
κB antagonist (v∆A49), creating vMC159 and vMC160. vMC160 slightly increased v∆A49 33 
virulence in the intranasal and intradermal routes of inoculation. vMC159 infection was less 34 
virulent than v∆A49 in both inoculation routes. vMC159-infected ear pinnae did not form lesions, 35 
but virus replication still occurred. Thus, the lack of lesions was not due to abortive virus 36 
replication. This system provides a new approach to examine MCV immunoevasion proteins 37 
within the context of a complete and complex immune system. 38 
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Molluscum contagiosum virus (MCV) is dermatotropic poxvirus, and is the etiological 52 
agent of molluscum contagiosum (MC) [1]. MCV infections are common and worldwide [2, 3]. 53 
MCV infects keratinocytes and infections can persist for months to years [4]. MC neoplasms are 54 
small and have little inflammation associated with them [1]. Lesions that spontaneously regress 55 
have increased numbers of apoptosing cells, cytotoxic T cells, natural killer cells, and type I IFN-56 
expressing plasmacytoid dendritic cells [5]. Thus, it is presumed that one key to MCV 57 
persistence lies in MCV modulating the host response.  58 
Very little is known about MCV immune evasion strategies as compared to other viruses.  59 
This is because MCV is refractive to growth in standard tissue culture. The sequencing of the 60 
MCV genome revealed that MCV encodes at least 40 known or predicted immune evasion 61 
molecules [6, 7]. Several of these proteins were characterized by studying them independent of 62 
MCV infection [4, 8-11]. However, it remains unknown how these MCV immune evasion 63 
molecules play a role in viral pathogenesis.  64 
 To overcome this technical barrier, we chose to deliver MCV immune evasion proteins 65 
(MC159 and MC160) to mice during a related poxvirus (VACV) infection. MC159 and MC160 66 
were examined because each protein inhibits NF-κB activation, yet each uses different 67 
mechanisms to antagonize the NF-κB activation pathway [12-15]. We chose VACV because it is 68 
the best-studied poxvirus [16], and there are several excellent animal models of VACV infection 69 
that afford studying the impact of viral immune evasion molecules on viral pathogenesis [17-20].  70 
Additionally, we published that MC159 and MC160 inhibit NF-κB and IRF3 activation in murine 71 
cell lines [21].  Further, Randall et al show that MC159 interacts with murine NEMO [15].  We 72 
also have unpublished data showing that MC160 induces murine IKK1 degradation, similar to 73 
MC160’s effect on human IKK1 [13, 14]. Thus, even though MCV is a human pathogen, it is 74 
likely that MC159 and MC160 interact with some of the known equivalent murine binding 75 
partners involved in immune surveillance. 76 
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 VACV strain v∆A49 was used as the parental virus, Fig. 1(a). v∆A49 lacks A49, which is 77 
an NF-κB antagonist [22]. We chose this virus because v∆A49 is moderately decreased in 78 
virulence [22], and because MC159 and MC160 are reported to inhibit NF-κB activation [12, 14, 79 
15]. Furthermore, MC159 and MC160 each act upstream of A49 [12, 14, 15, 22]. Thus, insertion 80 
of MC159 or MC160 into v∆A49 might restore v∆A49 virulence.  81 
The MC159L and MC160L genes were stably inserted into v∆A49, a virus construct that 82 
deleted nucleotides 113-473 of the A49R gene [22], Fig. 1(a). The expression of MC159L and 83 
MC160L was controlled by the VACV p7.5 promoter to ensure MCV gene expression 84 
throughout VACV infection. Of course, the expression profile for these MCV genes in VACV 85 
may differ from that of its profile during a natural MCV infection. The creation of vMC159 was 86 
described previously [12].  The strategy for constructing vMC160 was similar. 87 
To create vMC160, an MC160L gene under the control of the VACV p7.5 promoter was 88 
inserted into the p∆A49MCS plasmid [12]. p∆A49MCS contains a mutated A49R gene lacking nt 89 
113-473 that is flanked by a portion of the A48R and A50R genes [12]. The A48 flank begins at 90 
A48R nt 457 and continues through to A49R nt 112 for a 338-bp product [12]. It also possesses 91 
multiple cloning sites for insertion of the MC160L gene [12]. To create MC160/p∆A49MCS, the 92 
MC160L gene was PCR amplified from MC160/pCI [13] using forward primer 5’-93 
GGATCTATAATCATGGCGCACGAGCCA -3’ and reverse primer 5’- 94 
CTAGACTAGTCTAGTAGGAAGCTTTCGTT-3’ 95 
to yield a 1212-bp PCR product.  The MC160 nucleotides are underlined.  The reverse primer 96 
for MC160 engineered in the Spe I restriction enzyme digestion site (italicized). The p7.5 97 
promoter was PCR amplified from pUC13/gpt/EGFP [22], yielding a 121-bp product.  The 98 
forward primer was 5’-TTTTATCGATTAAATAATAAATACAATAATTAATTTCTCGT-3’ and the 99 
reverse primer was 5’- CTCGTGCGCCATGATTATAGATCCGTCACTG-3’and this yielded a 100 
121-bp PCR product.  The forward primer introduced a ClaI restriction enzyme site (italicized).  101 
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Next, 50-100 ng of the gel-purified PCR products were joined by SOE, and PCR amplified using 102 
the A48R forward and A50R reverse primers described in Biswas et al [12]. The resultant PCR 103 
product (1433 bp) was digested with ClaI and SpeI and inserted into p∆A49MCS that had been 104 
digested with ClaI and SpeI and treated with SAP. This plasmid was named 105 
MC160/p∆A49MCS. 106 
To create vMC160, CV-1 cells were infected with vΔA49 and transfected with pMC160 107 
and transient dominant selection was used, as described previously [23]. Recombinant viruses 108 
were collected 24 h later selected in the presence of mycophenolic acid, xanthine and 109 
hypoxanthine [23]. This process was repeated three times to isolate recombinant viruses away 110 
from parental viruses. Intermediate EcoGPT+ viruses were resolved into vMC160 by plaquing on 111 
BSC-1 cells in the absence of drugs.    112 
As shown in Fig. 1(b), the genotype of vMC160 was confirmed by using PCR analysis. 113 
Note that the 362-bp amplicon from v∆A49-infected cells increased in size to 1,692 bp, 114 
reflecting insertion of the 883-bp and 1,333-bp MC160L insert. Similarly, there was an 883-bp 115 
product when PCR amplifying the region flanking MC159L, as expected. Finally, the 55-kDa 116 
MC160 protein expression was detected in infected cells as early as 2 h (post-infection) p.i. and 117 
remained detectable at 24 h p.i. using polyclonal antiserum specific MC160 [24], Fig. 1(c). As 118 
previously reported, the 31-kDa MC159 protein was also detected using anti-MC159 antiserum. 119 
The VACV E3 protein, an early protein, was detected throughout infection, as predicted [25]. 120 
Actin levels were similar in each lane, showing even protein loading. 121 
Intranasal (IN) inoculation allows examination of VACV virulence; VACV initially infects 122 
the lungs and then spreads to the brain and other distal organs [17, 26]. BALB/c mice were 123 
inoculated IN with 5 X 103 p.f.u. of a virus as described [27]. Mice were examined daily and we 124 
used a 5-point scoring system that determines the extent of illness [28, 29]. This was performed 125 
as a blinded study to minimize potential bias. We only analyzed the planned comparisons of 126 
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v∆A49 to either vMC159, vMC160 or v∆A49rev, and set P values of <0.05 (indicated by one 127 
asterisk), P <0.01 (as indicated by two asterisks) and P < 0.0001 (as indicated by 4 asterisks) 128 
as criteria for statistical significance for these and the remaining assays involving mice. 129 
PBS-inoculated mice showed no signs of illness at any time point. v∆A49rev, which is 130 
equivalent to wild type VACV strain WR, triggered clinical signs of illness similar to results 131 
reported previously [22] (Fig. 2A). v∆A49 infection delayed illness onset, and clinical scores 132 
were consistently lower than v∆A49rev-infected mice as noted previously [22]. These 133 
differences were statistically significant on days 7-13 p.i. (Fig. 2A).  vMC159 infection appeared 134 
to cause a milder disease; the clinical scores from vMC159-infected mice were lower than 135 
v∆A49-infected mice from days 8 -12 p.i., and these differences were statistically significant on 136 
days 8, 9, and 11-13 post-infection, Fig. 2(a). In comparison to v∆A49 infection, mice infected 137 
with vMC160 had increased signs of illness, Fig. 2(a). These differences were statistically 138 
significant at days 7 and 8 post-infection, Fig. 2(a). These data suggest that the MC159L gene 139 
reduced the virulence of v∆A49 while MC160L partially substituted for A49L.  140 
Weight loss is an additional measure of virus virulence for IN inoculations [30]. The 141 
same mice as in Fig. 2(a) were also weighed daily, and data were expressed as the percentage 142 
of the mean of each individual animal’s weight loss from day 0 +/- SEM [27]. Results are shown 143 
in Fig. 2(b). We only analyzed the planned comparisons of v∆A49 to either vMC159, vMC160 or 144 
v∆A49rev. v∆A49rev infection caused weight loss similar to that reported previously [22]. 145 
v∆A49-infected mice lost less weight than v∆A49rev-infected mice as expected [22], and these 146 
differences were statistically significant on days 8-12 p.i., Fig. 2(b). vMC159 caused less weight 147 
loss than v∆A49 at days 8-15 p.i. although these differences in weight were not statistically 148 
significant. vMC160-infected mice also weighed slightly more than v∆A49-infected mice at days 149 
8-12 p.i., but these differences were not statistically significant. These data suggested that 150 
MC159 decreased virus virulence to a greater extent than vMC160 in the IN infection model.  151 
 7 
The intradermal (ID) inoculation of a mouse ear pinna provides an alternative model to 152 
examine VACV virulence [19, 31]. In this case, lesion formation and lesion size is used to 153 
quantify virulence [18]. One could argue that ID inoculations most closely represent the location 154 
of natural, dermatotropic MCV infections. There also are some parallels in the immune 155 
responses to ID VACV infections and MCV infections. For example, type I IFN appears to be 156 
important in controlling lesion size in VACV-infected ears [32] and lesion resolution during MCV 157 
infections [5].   158 
For ID inoculations, C57BL/6 mice were inoculated ID in the left ear dorsal pinna with 159 
104 PFU of each virus as described in [27]. The infected ears were examined daily for the next 160 
18 days for the presence of lesions, and results are shown in Fig. 3(a). We only analyzed the 161 
planned comparisons of v∆A49 to either vMC159, vMC160 or v∆A49rev. For all virus infections, 162 
no lesions were visually detected for the first six days p.i., a routine observation [27]. Gross 163 
lesions were observed in v∆A49rev-infected mice starting on day 7 p.i., and lesion size 164 
increased until day 12, and then resolved from days 13-18.  v∆A49-induced lesion sizes were 165 
slightly smaller than v∆A49rev at all times examined, and were statistically significant only on 166 
days 10 and 11 p.i. vMC160-associated lesions were similar in size to lesions produced by 167 
v∆A49rev and slightly larger that v∆A49-induced lesions. When comparing lesions from 168 
vMC160- versus v∆A49-infected mice, vMC160 lesions were significantly larger on days 7,8 and 169 
10 p.i., indicating that MC160 may increase virulence partially. Surprisingly, vMC159 inoculation 170 
did not produce a lesion at any point in time, Fig 3(a) and (b). 171 
The most striking results observed were those for the ID model of infection, and that 172 
there was a complete lack of lesion formation during vMC159 infection. Only 2 other VACV 173 
strains have been reported to not cause lesion formation in skin: v∆A36R and NYVAC [18, 33]. 174 
v∆A36R and NYVAC cannot spread from cell-to-cell efficiently in vitro [18, 33, 34]. It is thought 175 
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that ∆A36R or NYVAC do not cause lesions because they spread less efficiently to neighboring 176 
cells in vivo, resulting in an abortive infection process.   177 
One question was why vMC159 would cause no lesions. vMC159 and vMC160 each 178 
replicated to the same levels as v∆A49 using either one-step or multi-step growth curve assays 179 
in mouse embryo fibroblasts (MEFs) (data not shown). Also, vMC159- and vMC160-formed 180 
plaques were similar to v∆A49 and vA49 in MEF and BSC40 cellular monolayers (data not 181 
shown). Thus, it was unlikely that vMC159 spreads less efficiently for reason suspected for 182 
v∆A36R and NYVAC. Another possibility was that MC159 and MC160 may not interact with the 183 
murine homologs of their binding partners.  This is also unlikely because MC159 interacts with 184 
murine NEMO [15] and MC160 interacts with murine IKK1 (data not shown).  Next, viral titers 185 
were quantified at 3, 5 and 11 days p.i. [27]. Maximum VACV titers are detected at day 5 p.i. 186 
[19], and we chose these time points to detect virus replication prior to and after maximal 187 
replication. vMC160 titers were not examined because vMC160-induced ear lesions were 188 
similar to those for v∆A49 and v∆A49rev. 189 
Data are shown in Figure 3 as both p.f.u. per ear Fig. 3(c) and PFU per gram of tissue 190 
Fig. 3(d). The starting inoculum was 104 p.f.u. in each ear pinna [27]. Data showed that all 191 
viruses replicated because virus titers were higher than the initial inoculum (104 p.f.u.) on days 3 192 
and 5 p.i. vMC159 titers were lower than the wild-type (vA49rev) or parental (v∆A49) viruses at 193 
all times tested. v∆A49 and v∆A49rev titers increased to approximately 1.3 x106 by day 3 p.i. 194 
(Fig. 3C). In contrast, vMC159 titers were 1.2 x 105 p.f.u. at day 3 p.i. All viruses continued to 195 
replicate during the next 48 h because titers increased between 3 and 5 days p.i. By day 11 p.i., 196 
virus replication had waned, as indicated by the decrease in virus titers. Note that the decrease 197 
in virus titers from day 5 to day 11 p.i. implies that there is indeed immune mediated clearance 198 
of virus, but this occurred without accompanying inflammation. 199 
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One could argue that no lesions arise because vMC159 titers are lower than v∆A49 in 200 
ear pinnae. Indeed, it is unclear what the threshold of virus titer is needed for lesion formation. 201 
Tscharke et al. showed that inoculation with as little as 102 p.f.u. of VACV induces ear lesions 202 
formation [18]. vMC159 titers greatly exceed that amount at days 3 and 5 p.i. This suggests that 203 
vMC159 decouples replication from lesion formation. Interestingly, both ∆A36R and NYVAC 204 
elicit protective immune responses (e.g., antibody production) [18, 35]. Thus, it is tempting to 205 
ask if vMC159 also retains its immunogenicity and, if so, if vMC159 would be useful for the 206 
vaccine field. 207 
It is not yet clear how MC159 suppresses lesion formation, and this is a direction for 208 
future studies. It is appreciated that VACV lesions are due, in part, to immunopathology 209 
because smaller lesions are associated with decreases in expression of multiple cytokines and 210 
chemokines [27, 36]. Thus, MC159 may either directly or indirectly prevent expression of these 211 
host cell proteins to halt pro-inflammatory processes. In this case, the MC159 ability to inhibit 212 
NF-κB and IRF3 activation may be relevant. MC159 inhibits apoptosis while MC160 does not 213 [24, 37]. Another speculation, then, is that this anti-apoptotic property of MC159 affords virus 214 
attenuation, perhaps by allowing virus-infected cells to survive for prolonger time periods. 215 
Interestingly, a mutant VACV lacking an apoptosis antagonist (∆B13R) has an increased lesion 216 
size as compared to wild-type VACV [18], showing an instance where inhibition of apoptosis 217 
diminishes lesion formation.  218 
This is the first report that examines MCV immune antagonists in the context of an animal 219 
infection. MC159 and MC160 are members of the FLIP family of proteins [4]. They each 220 
possess tandem death effector domains (DEDs) that share 43% similarity. MC159 and MC160 221 
also share some biological features, including inhibition of NF-κB and IRF3 [4]. Despite their 222 
similarity, MC159 and MC160 likely have distinct roles during MCV infection in vivo, as indicated 223 
by data here.  VACV itself expresses at least 10 different NF-κB inhibitory proteins [20], 224 
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indicating that control of this pathway is critical for survival of VACV in vivo. Perhaps MCV also 225 
expresses MC159 and MC160, along with the two other known MCV NF-κB antagonists 226 
(MC005, MC132), for similar reasons when confronting a complex, multi-faceted anti-viral 227 
immune response [10, 11]. 228 
 To date, there is no cell culture system or laboratory animal model to study MCV 229 
replication and pathogenesis. Researchers have used creative approaches to extrapolate the 230 
biological importance of MC159 as an immune evasion molecule. This includes the 231 
development of transgenic mouse strains that express MC159 [38, 39] or using murine 232 
cytomegalovirus to express MC159 [40]. Our system uses VACV during ID mouse infections, 233 
and is perhaps the model closest to mimicking MCV infection at this current time. One could 234 
argue that the addition of MC159 to v∆A49 resulted in a disease that mimics MC because, like 235 
MC, there is little inflammation.  236 
The current study demonstrates the biological effects of two well-characterized MCV 237 
immune evasion proteins in a newly-created system. MCV encodes at least 40 other known or 238 
predicted immune evasion molecules [6, 7]. Thus, studies of MCV immune evasion molecules 239 
provide a rich opportunity to identify novel aspects of virus-host interactions during persistent 240 
infections.  The surrogate system described here now affords these types of studies to better 241 
understand MCV pathogenesis and persistent virus infections.  242 
  243 
 244 
 245 
 246 
 247 
 248 
 249 
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Figure Legends 250 
Figure 1. Characterization of vaccinia viruses expressing either MC159 or MC160.  (A) A 251 
schematic of the viruses used in this study, focusing on the portion of the VACV WR genome 252 
containing the A49R gene and portions of the A48R and A50R genes flanking A49R. v∆A49 is a 253 
VACV strain in which A49R nucleotides 113-473 are deleted. Either the MCV MC159L or the 254 
MC160L genes, each under the control of the VACV p7.5 promoter, were inserted into v∆A49 to 255 
create vMC159 or vMC160, respectively. U5NU is the early gene transcription termination 256 
signal. (B) BSC40 monolayers were either mock-infected or infected with the indicated viruses 257 
(MOI = 10). At 24 h p.i., cells were collected, and DNA was isolated. DNA was PCR amplified 258 
using a forward primer specific for A48R and reverse primer specific for A50R [22]. A portion of 259 
each PCR reaction was analyzed by gel electrophoresis. Bands were detected by ethidium 260 
bromide staining of the gel. (C) BSC40 monolayers were either mock-infected or with v∆A49, 261 
vMC159 or vMC160 (MOI = 10). Cells were lysed at the indicated times and 15 μg of clarified 262 
cellular lysates were subjected to immunoblotting for the presence of MCV (MC159, MC160) or 263 
VACV (E3) proteins or cellular β-actin. 264 
 265 
Figure 2. The effect of MCV genes on virus virulence using the intranasal route of 266 
infection. Female BALB/c mice (n = 5 per group) were inoculated IN with 5 X 103 p.f.u. v∆A49, 267 
v∆A49rev, vMC159, or vMC160 or PBS. (A) Clinical signs of illness were monitored daily for 15 268 
days and scored from 0-5. Clinical scores were expressed as the mean for each group. One-269 
way ANOVA was performed followed by Tukey’s multiple comparison test to determine 270 
statistical significance. Asterisks indicate the days on which clinical signs of illness induced were 271 
significantly different between the indicated groups. (*P < 0.05, **P < 0.01 or ****P < 0.0001). 272 
(B) Mice were weighed daily, and data were expressed as the percentage of weight change 273 
from day 0. To determine statistically significant differences between weight change during virus 274 
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infection, two-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test, 275 
was performed. Asterisks indicate the days on which weight change induced by v∆A49 were 276 
significantly different from those induced by v∆A49rev (*P < 0.05). 277 
 278 
Figure 3. The effect of MCV genes on virus virulence using the intradermal route of 279 
inoculation. C57BL/6 mice (n = 5 per group) were infected ID with 104 p.f.u. v∆A49, v∆A49rev, 280 
vMC159, or vMC160 in the left ear pinna. Lesion size was expressed as the mean for the group 281 
+/- SEM. (A) Sizes of resulting lesions were measured daily for 18 days. The lesion size was 282 
measured by using a 0.01-mm digital caliper. The data are expressed as the means of lesion 283 
sizes ±SEM. Statistical significance was determined by two-way ANOVA, followed by Tukey’s 284 
multiple comparison test. The asterisks indicate the days on which the lesion size caused was 285 
statistically significantly between indicated groups (*P < 0.05 or ****P < 0.0001). (B) 286 
Representative images of inoculated ear pinnae at 10 days p.i. v∆A49-infected mice (left panel) 287 
or vMC159-infected mice (right panel). (C and D) At the indicated days p.i., ears were collected, 288 
homogenized, and lysed, and viral titers of the lysates were determined by plaque assay. Each 289 
symbol represents the virus titer from an individual animal, and the mean titer is indicated by a 290 
line. Data are expressed as the mean titer of virus (p.f.u.) per gram of tissue (D) and as the total 291 
p.f.u. per ear (C). Statistical significance was determined by Kruskal-Wallis test. The asterisk 292 
indicate data points at which titers of viruses were statistically significantly different from the 293 
other (*P < 0.05).  294 
 295 
 296 
 297 
 298 
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